Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis

Pharmacognosy Research

Volumn 6, Issue 2, 2014, Pages 153-162

  Surapaneni, Krishna Mohan ^a   Jainu, Mallika ^b  

^a SAVEETHA UNIVERSITY   (India)

^b SSN COLLEGE OF ENGINEERING   (India)

Author keywords

Biochemical parameters; experimentally induced NASH; hydroxy citric acid; liver marker enzymes; non alcoholic fatty liver disease; non alcoholic steatohepatitis; pioglitazone; quercetin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HYDROXYCITRIC ACID; LACTATE DEHYDROGENASE; PIOGLITAZONE; QUERCETIN; SERUM ALBUMIN; UREA; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; INJURY SEVERITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER INJURY; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 84897972923     PISSN: None     EISSN: 09748490     Source Type: Journal    
DOI: 10.4103/0974-8490.129037     Document Type: Article

References (42)

1. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906. (Pubitemid 40824701)
2. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40 (Suppl 1):S5-10.
3. Cusi K. Non-Alcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009;16:141-9.
4. Kakadiya J, Shah N. Effect of some synthetic and herbel drugs on tumer necrosis factor alpha in renal reperfusion induced renal damage in type 2 diabetic rats. Int J Preclinical Pharm Res 2011;2:30-7.
5. Molina MF, Sanchez-Reus I, Iglesias I, Benedi J. Quercetin, a flavonoid antioxidant, prevents and protects against ethanol-induced oxidative stress in mouse liver. Biol Pharm Bull 2003;26:1398-402. (Pubitemid 41685388)
6. Alexandra B and Bentz A. Review of Quercetin: Chemistry, Antioxidant Properties and Bioavailability. J Young Investig 2009;19: Retrieved 6 October 2012. Available from: http://www. jyi.org/research/re.php?id=3416.
7. Shara M, Ohia SE, Schmidt RE, Yasmin T, Zardetto-Smith A, Kincaid A, et al. Physico-chemical properties of a novel (?)-hydroxycitric acid extract and its effect on body weight, selected organ weights, hepatic lipid peroxidation and DNA fragmentation, hematology and clinical chemistry and histopathological changes over a period of 90 days. Mol Cell Biochem 2004;260:171-86. (Pubitemid 39127585)
8. Bennet GJ, Lee HH. Xanthones from Guttiferae. Phytochemistry 1989;28:967-98.
9. Minami H, Kinoshita M, Fukuyama Y, Kodama M, Yoshizawa T, Sugiura M, et al. Antioxidant xanthones from Garcinia subliptica. Phytochemistry 1994;36;501-6.
10. Surapaneni KM, Saraswathi P and Jainu M. Non alcoholic steatohepatitis (NASH) experimental model induction in rats. Int J Pharm Bio Sci 2012;3:1085-90.
11. Surapaneni KM, Sarswathi P and Jainu M. Role of pioglitazone, quercetin and hydroxy citric acid against non alcoholic steatohepatitis (NASH)-histological and scanning electron microscopy (SEM) studies in an experimental model of NASH. Asian J Pharm Clin Res 2012;5:244-7.
12. King J. The hydrolases-Acid and alkaline phosphatses. In Practical Clinical Enzymology. London: D. Von Nostrand Co. Ltd; 1965. p. 191-208.
13. Mohur AF, Cooke IJ. Simple method of measuring serum level of glutamate oxaloacetic acid and glutamate pyruvate transaminase in routine laboratories. J Clin Pathol 1975;10:394-9.
14. Nieland AA. Lactic acid dehydrogenase of heart muscle. Methods in Enzymology-I, Academic Press, New York and London 1955. p. 449-54.
15. Moss DW, Henderson AR. Clinical enzymology. In: Burtis CA, Ashwood ER, editors. Tietz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders Company; 1999. p. 617-721.
16. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80. (Pubitemid 20075105)
17. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
18. Angulo P. Management of NASH: Current and future perspectives on treatment. In: Farrell GC, George J, de laMHall P, McCullough AJ, editors. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell Publishing; 2005. p. 194-207.
19. Sakugawa H, Nakasone H, Nakayoshi T, Kawakami Y, Yamashiro T, Maeshiro T, et al. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan. Hepatogastroenterology 2003;50:2005-8. (Pubitemid 37467982)
20. Lee RG. Non-Alcoholic steatohepatitis: A study on 49 patients. Hum Pathol 1989;20:594-8.
21. Adler M, Schffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-6. (Pubitemid 10218835)
22. Oh MK, Winn Jand Poordad F. Review article: Diagnosis and treatment of non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;28:503-22.
23. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25. (Pubitemid 35231670)
24. Muoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis. Ann Hepatol 2009;8:123-8.
25. Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramrez JC, Castro MG. -Glutamyl transferase: A marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol 2012;24:805-10.
26. Choi JS, Yoon TJ, Kang KR, Lee KH, Kim WH, Suh YH, et al. Glycoprotein isolated from Acanthopanax senticosus protects against hepatotoxicity induced by acute and chronic alcohol treatment. Biol Pharm Bull 2006;29:306-14.
27. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-c ligand rosiglitazone. Hepatology 2003;38:434-40.
28. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010;51:445-3.
29. Coskun O, Kanter M, Korkmaz A, Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and -cell damage in rat pncreas. Pharmacol Res 2005;51:117-23. (Pubitemid 40040541)
30. Rivera L, Morn R, Snchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats. Obesity 2008;16;2081-7.
31. Kobori M, Masumoto S, Akimoto Y, Takahashi Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin induced disturbance of hepatic gene expression in mice. Mol Nutr Food Res 2009;53:859-68.
32. Chen X. Protective effects of quercetin on liver injury induced by ethanol. Pharmacogn Mag 2010;6:135-41.
33. Collantes R, Ong JP, Younoss ZM. Nonalcoholic fatty liver disease and the epidemic of obesity. Cleve Clin J Med 2004;71:657-64. (Pubitemid 39193341)
34. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010;16:4784-91.
35. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-44. (Pubitemid 32927998)
36. Munoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in group of mexican patients with non alcoholic steatohepatitis. Ann Hepatol 2009;8:123-8.
37. Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond) 2004;1:10.
38. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008;31:361-2. (Pubitemid 351213351)
39. Czerny B, Put A, My?liwiec Z, Juzyszyn Z. The Influence of Quercetin on Some Biochemical Parameters in Rats Exposed to Environmental Contamination with Fluorine Compounds. Polish J Environ Stud 2000;9:157-61.
40. Sullivan AC, Triscari J, Miller ON. The influence of (-)- hydroxycitrate on in ViVo rates of hepatic glycogenesis and cholesterogenesis. Fed Proc 1974;33:656.
41. Bousova I, Bacikova E, Dobrijevic S, Drsata J. Glycation of aspartate aminotransferase by methylglyoxal, effect of hydroxycitric and uric acid. Mol Cell Biol 2009;331:215-23.
42. Chattopadhyay RR, Sarkar SK, Ganguly S, Banerjee RN, Basu TK, Mukherjee A. Hepatoprotective activity of Azadirachta indica leaves on paracetamol induced hepatic damage in rats. Indian J Exp Biol 1992;30:738-40.